5 Best Healthcare Technology Stocks To Invest In Right Now

There is a steady stream of recent electric vehicle sector or related stock news from�the likes of Tesla Motors Inc (NASDAQ: TSLA), Kandi Technologies Group Inc (NASDAQ: KNDI), HydroPhi Technologies Group, Inc (OTCMKTS: HPTG) and Green Automotive Co (OTCMKTS: GACR) that you might want to be paying attention to:

Tesla Vs. Car Dealers. In an effort to protect traditional car dealers and the sales tax revenue they generate, New Jersey is banning Tesla stores selling Tesla cars directly to consumers (Arizona and Texas also ban the direct sale of vehicles from manufacturers to consumers) plus the company is�battling a bill in Ohio that would also force it to go through franchise dealers in that state. Various media outlets like WIRED (New Jersey Bans Tesla to Ensure Buying a Car Will Always Suck), the Wall Street Journal (Tesla to Stop Selling Electric Cars in New Jersey�and Tesla Beware: What Happened to the Last Guy Who Annoyed Car Dealers) and Yahoo! Finance (New Jersey's Tesla ban makes sense compared to these silly laws) all have had good articles covering the controversy.�However, such bans are more or less a mote issue as customers who really want Teslas can easily circumvent rules�by purchasing vehicles online and taking delivery in other locations. Moreover, the controversy has had little impact on Tesla shares which are flat this week and�up 56% since the start of the year, up 518.1% over the past year and up 1,138.5% since July 2010.

Top Healthcare Technology Stocks For 2015: ING Risk Managed Natural Resources Fund (IRR)

ING Risk Managed Natural Resources Fund the (Fund) is a non- diversified, closed-end management investment company. The Fund�� investment objective is total return through a combination of current income, capital gains and capital appreciation. The Fund will seek to achieve its investment objective by investing in a portfolio of equity securities of companies in the energy and natural resources industries. ING Investments, LLC is the Fund�� investment adviser.

The Fund seeks to achieve its investment objective by investing at least 80% of its managed assets in the equity securities of, or derivatives linked to the equity securities of companies that are primarily engaged in owning or developing energy, other natural resources and basic materials, or supplying goods and services to such companies (Natural Resources Companies). Equity securities held by the Fund could include common stocks, preferred shares, convertible securities, warrants and depository receipts.

The Fund�� top 10 holdings include ExxonMobil Corp., Chevron Corp., ConocoPhillips, Schlumberger Ltd., Occidental Petroleum Corp., Marathon Oil Corp., Valero Energy Corp., Hess Corp., XTO Energy, Inc. and EI DuPont de Nemours & Co.

Advisors' Opinion:

• [By Value Digger]

  Manitok's total cost per Well (Drill, Case, Complete, Equip & Tie) is about $5.5 million. With average reserves per well ranging from 300 to 850 MMboe, the average payout is about 1.5 years and the peak Internal Rate of Return (IRR) reaches even 150% in some of the most productive properties of the company. Considering the company's balanced production mix, the average operating netback for 2013 is strong and hovers at approximately $33/boe.

5 Best Healthcare Technology Stocks To Invest In Right Now: Uroplasty Inc (UPI)

Uroplasty, Inc., incorporated in January 1992, is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions. The Company�� primary focus is on two products: the Urgent PC Neuromodulation system and Macroplastique Implants. The Urgent PC system is a United States Food and Drug Administration (FDA)-approved minimally invasive, office-based neuromodulation therapy for the treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency, and urge incontinence; and Macroplastique Implants a urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency (ISD). Outside of the United States, the Company�� Urgent PC is also approved for treatment of fecal incontinence, and Macroplastique is also approved for treatment of male stress incontinence and vesicoureteral reflux.

Urgent PC Neuromodulation System

Using a small-gauge needle electrode inserted above the ankle, the Urgent PC System delivers electrical impulses to the tibial nerve that travel to the sacral nerve plexus, a control center for pelvic floor and bladder function. Components of the Urgent PC system include a hair-width needle electrode, a lead set, and an external, handheld, battery-powered stimulator. For each 30-minute, office-based therapy session, the physician or other qualified healthcare provider inserts the needle electrode in the patient�� lower leg and connects the electrode to the stimulator. Typically, a patient undergoes 12 consecutive weekly treatment sessions, with follow-up maintenance treatments as required to sustain the therapeutic effect. The Company has received regulatory clearances for sale of the Urgent PC system in the United States, Canada and Europe. It also has launched its second generation Urgent PC system.

Macroplastique

Macroplastique is designed to restore the patient�� urinary contine! nce immediately following treatment. Macroplastique is a soft-textured, permanent implant injected, under endoscopic visualization, around the urethra distal to the bladder neck. It is a composition of heat vulcanized, solid, soft, irregularly shaped polydimethylsiloxane (solid silicone elastomer) implants suspended in a biocompatible excretable carrier gel. Macroplastique does not degrade, is not absorbed into surrounding tissues and does not migrate from the implant site. The Company has sold Macroplastique for several urological indications in over 40 countries outside the United States.

Other Uroplasty Products

The Company markets outside of the United States minimally invasive products to address fecal incontinence. Its PTQ Implants offer minimally invasive, soft-textured permanent implant for treatment of fecal incontinence. The PTQ Implants are implanted circumferentially into the submucosa of the anal canal, creating a bulking and supportive effect similar to that of Macroplastique injection for the treatment of stress urinary incontinence. The PTQ is Conformite Europeenne (CE) marked and is sold outside the United States in various international markets. The Urgent PC is also CE marked and sold outside of the United States for the treatment of fecal incontinence. In addition to urological applications, the Company markets its tissue bulking material outside the United States for otolaryngology vocal cord rehabilitation applications under the trade name VOX Implants. In the Netherlands and the United Kingdom only, the Company distributes certain wound care products in accordance with a distributor agreement.

The Company competes with Pfizer Inc., Johnson and Johnson, Novartis, Allergan, GlaxoSmithKline, Carbon Medical Technologies, BioForm, Inc., Q-Med AB and Contura.

Advisors' Opinion:

• [By Lisa Levin]

  Uroplasty (NASDAQ: UPI) shares reached a new 52-week high of $5.22 after the company reported strong Q3 results.

  Juniper Networks (NYSE: JNPR) shares gained 8.23% to touch a new 52-week high of $28.15 after the company reported better-than-expected fourth-quarter results. Barclays upgraded the stock from Equalweight to Overweight and lifted the price target from $29.00 to $34.00.

5 Best Healthcare Technology Stocks To Invest In Right Now: NeurogesX Inc.(NGSX)

NeurogesX, Inc., a biopharmaceutical company, engages in developing and commercializing pain management therapies. The company offers Qutenza for the management of neuropathic pain associated with postherpetic neuralgia, and for the treatment of peripheral neuropathic pain in non-diabetic adults. It also develops NGX-1998, which has completed Phase 2 clinical study, is a topical liquid formulation of high concentration capsaicin to treat neuropathic pain conditions; and acetaminophen prodrugs that is in preclinical stage for use in acute pain, including traumatic pain, post-surgical pain, and fever. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is headquartered in San Mateo, California.

Advisors' Opinion:

• [By CRWE]

  Today, NGSX has shed (-6.67%) down -0.0005 at $.0070 with 29,206 shares in play thus far (ref. google finance Delayed: 10:44AM EDT July 17, 2013), but don�� let this get you down.

  Acorda Therapeutics, Inc. previously reported it has acquired two neuropathic pain management assets from NeurogesX, Inc. (OTCBB: NGSX). Qutenza庐 is approved by the U.S. Food and Drug Administration (FDA) for the management of neuropathic pain associated with postherpetic neuralgia. The Company also acquired NP-1998, a Phase 3 ready, prescription strength capsaicin topical solution, being assessed for the treatment of neuropathic pain. NP-1998 was previously referred to as NGX-1998.

5 Best Healthcare Technology Stocks To Invest In Right Now: Mint Corp (MIT)

The Mint Corporation is a vertically integrated prepaid card and payroll services provider with its own ATM network, payment processing platform and branded card product, including microcredit, mobile top up and money remittance services delivered seamlessly to workers globally. The Company operates through Mint Middle East LLC (MME), Mint Capital LLC (MCO), Mint Global Processing LLC (MGP) and Mint Electronic Payment Services LLC (MEPS). MME is a payroll card services provider facilitating an automated and secure payroll system to employers in the United Arab Emirates (UAE). MGP is an integrated third party processing platform and operates as a third party transaction processor to be based in the UAE. MCO manages the microfinance product in collaboration with Mawarid Finance PJSC. MEPS was formed to operate the business assets acquired from ePAY, a division of Global Business Systems for Multimedia. Advisors' Opinion:

• [By Rahul Chattaraj]

  Ford Motor (F) announced on Wednesday that it would start working with two U.S. universities to initiate research for driverless cars. The carmaker has teamed up with Stanford University and the Massachusetts Institute of Technology (MIT) to work out ways to overcome ��echnical challenges��surrounding this segment.